![Epic Games: Fortnite is offline for Apple devices worldwide after app store rejection [updated]](https://helios-i.mashable.com/imagery/articles/00T6DmFkLaAeJiMZlCJ7eUs/hero-image.fill.size_1200x675.v1747407583.jpg)
.jpg)
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Bad news keeps coming for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. Earlier this week, a study published in The New England Journal of Medicine revealed that patients taking Eli Lilly's Zepbound lost more weight than patients taking Novo Nordisk's Wegovy. However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to soar 35% over the next 12 months.Image source: Getty Images.Continue reading
Bad news keeps coming for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer. Earlier this week, a study published in The New England Journal of Medicine revealed that patients taking Eli Lilly's Zepbound lost more weight than patients taking Novo Nordisk's Wegovy.
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to soar 35% over the next 12 months.
Image source: Getty Images.
